Search

everythinglearnresearchcommunity

for

Search:↓

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

Hair multiplication or cloning is not available anywhere in the world. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

A person had success with micro-needling for hair growth but stopped and noticed hairline recession. They plan to restart treatment at age 40, using micro-needling, oral minoxidil, finasteride, a laser cap, topical minoxidil with tretinoin, collagen, and other supplements.

A user shared progress pictures showing significant hair regrowth after using 1mg finasteride and weekly microneedling for about 2.5 to 3 months. The user reported no side effects and maintained good health and mood.

The conversation is about exploring alternatives for hair loss treatment, specifically ds laboratory revita shampoo and nanoxidil, with the user currently using microneedling. The user is considering these options due to fewer side effects compared to other treatments.

The conversation is about hair loss treatments, specifically asking for updates on verteporfin research following promising results. No specific treatments were discussed in the provided text.

The user is experiencing promising hair regrowth after 10 weeks of using oral minoxidil and finasteride, with noticeable new hair growth. They report no significant side effects, except for some unexpected hair growth in new areas.

The conversation humorously discusses hair loss treatments, including finasteride, dutasteride, minoxidil, and microneedling. The user shares progress and thanks the pharmaceutical industry, with comments on the effectiveness and side effects of these treatments.

The conversation is about a person's two-year hair regrowth progress using finasteride, minoxidil, ketoconazole, and microneedling. They are comparing their hair from April 21, 2022, to April 13, 2024.

Two twins who used Minoxidil, finasteride and dermarollers to treat their androgenic alopecia over a 10 month time period. The user is providing details on the process they use for dermarolling.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

. CumsOnYourFeet69 has been discussing a new treatment called CosmeRNA which claims to target the root cause of male pattern baldness, and is considering using it in conjunction with Minoxidil instead of Finasteride due to possible side effects. Replies have highlighted that the efficacy of this treatment is still unknown, but it could be used as an effective maintenance option if successful.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

Verteporfin might reverse severe hair loss but is still in early testing stages. It could be a future option for NW6-7, though expensive.

The user received 1600 hair grafts but is dissatisfied and plans a second transplant for better coverage. They use minoxidil and finasteride and are considering adding dutasteride.

The conversation discusses hair loss treatments, including finasteride, topical and oral minoxidil, and the potential use of dutasteride. The user shares progress and seeks advice on whether to start dutasteride, noting positive results with current treatments but concerns about long-term effects.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

The user has been using finasteride and minoxidil for 5 years with initial success but is now experiencing hair thinning despite increasing dutasteride usage. They are considering adjusting dutasteride frequency and possibly adding treatments like eucapil, minoxidil, and GHK-Cu peptides.

A user shared their 8-year journey with hair loss treatments, including oral minoxidil, dutasteride, Propecia, and a 2500 FUT hair transplant, leading to significant hair regrowth and a healthy lifestyle. They experienced some side effects like oily skin and a higher-pitched voice but maintained high testosterone levels and a strong libido.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.

A 20-year-old started taking 1mg oral finasteride and 3mg oral minoxidil every other day for hair loss. They plan to focus on their hair and health over the summer and will update in November.

The conversation discusses hair cloning progress and mentions treatments like Minoxidil, finasteride, and RU58841. Users also talk about hair transplants and their effectiveness.